MindWalk Holdings (HYFT) Change in Receivables (2023 - 2026)
MindWalk Holdings (HYFT) posted quarterly Change in Receivables of -$483662.5 for Q2 2026, down 13.95% year-over-year from -$562077.4 in Q2 2025, and down 170.8% quarter-over-quarter from $683100.1 in Q1 2026.
MindWalk Holdings (HYFT) Change in Receivables (2023 - 2026) Analysis & Trends
MindWalk Holdings (HYFT) has reported Change in Receivables for 4 consecutive years, with -$483662.5 the latest figure, recorded in Q2 2026.
- In Q2 2026, Change in Receivables fell 13.95% year-over-year to -$483662.5; the TTM figure through Apr 2026 stood at -$1.2 million (down 430.36% YoY), while the FY2026 annual figure was -$1.2 million, down 442.87% from the prior year.
- Change in Receivables fell to -$483662.5 in Q2 2026 per HYFT's latest filing, from $683100.1 in the prior quarter.
- Across five years, Change in Receivables topped out at $930417.5 in Q3 2024 and bottomed at -$1.1 million in Q4 2024.
- Historically, Change in Receivables has averaged -$124945.2 across 4 years, with a median of -$235449.4 in 2023.
- On a YoY basis, Change in Receivables climbed as much as 2103.02% in 2024 and fell as far as 9054.0% in 2024.
- MindWalk Holdings' Change in Receivables stood at $12537.4 in 2023, then slumped by 9054.0% to -$1.1 million in 2024, then jumped by 34.05% to -$740342.7 in 2025, then soared by 34.67% to -$483662.5 in 2026.
- Business Quant data shows HYFT's Change in Receivables at -$483662.5 in Q2 2026, $683100.1 in Q1 2026, and -$740342.7 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 117.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -483,662.49 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 31.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -483,662.49 |
| Apr 30, 2026 | -483,662.49 |
| Jan 31, 2026 | 683,100.08 |
| Jan 31, 2026 | 683,100.08 |
| Oct 31, 2025 | -740,342.74 |
| Oct 31, 2025 | -740,342.74 |
| Jul 31, 2025 | -618,617.53 |
| Jul 31, 2025 | -618,617.53 |
| Apr 30, 2025 | -424,448.13 |
| Apr 30, 2025 | -424,448.13 |
| Jan 31, 2025 | 398,001.17 |
| Jan 31, 2025 | 398,001.17 |
| Oct 31, 2024 | -1.12 Mn |
| Oct 31, 2024 | -1.12 Mn |
| Jul 31, 2024 | 930,417.46 |
| Jul 31, 2024 | 930,417.46 |
| Apr 30, 2024 | -767,021.09 |
| Apr 30, 2024 | -767,021.09 |
| Jan 31, 2024 | 358,025.20 |
| Jan 31, 2024 | 358,025.20 |